Disposition of 3380 shares by Ellen Rosenberg of Amicus Therapeutics at 13.44 subject to Rule 16b-3

FOLD Stock  USD 9.36  0.79  7.78%   
About 70% of Amicus Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Amicus Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Amicus Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Amicus Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Amicus Therapeutics Officer Chief Legal Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 3380 common stock at 13.44 of Amicus Therapeutics by Ellen Rosenberg on 31st of March 2024. This event was filed by Amicus Therapeutics with SEC on 2024-01-04. Statement of changes in beneficial ownership - SEC Form 4. Ellen Rosenberg currently serves as general counsel and corporate secretary of Amicus Therapeutics

Cash Flow Correlation

Amicus Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Amicus Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Amicus Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Amicus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Amicus Therapeutics Historical Investor Sentiment

Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Amicus Therapeutics.

Amicus Therapeutics Fundamental Analysis

We analyze Amicus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Amicus Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Amicus Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Amicus Therapeutics stock to make a market-neutral strategy. Peer analysis of Amicus Therapeutics could also be used in its relative valuation, which is a method of valuing Amicus Therapeutics by comparing valuation metrics with similar companies.

Peers

Amicus Therapeutics Related Equities

AGIOAgios Pharm   2.10   
0%
59.0%
HRMYHarmony Biosciences   1.27   
0%
36.0%
CYTKCytokinetics   0.72   
0%
20.0%
BPMCBlueprint Medicines   0.66   
0%
18.0%
MREOMereo BioPharma   0.27   
0%
7.0%
RVMDRevolution Medicines   0.00   
0%
0%
ARGXArgenx NV   0.00   
0%
0%
DYNDyne Therapeutics   0.00   
0%
0%
BMRNBiomarin Pharmaceutical   0.00   
0%
0%
DNLIDenali Therapeutics   0.00   
0%
0%
RAREUltragenyx   0.00   
0%
0%
DAWNDay One   0.47   
13.0%
0%
KURAKura Oncology   0.62   
17.0%
0%
INBXInhibrx   0.88   
25.0%
0%
LEGNLegend Biotech   1.04   
29.0%
0%
ARVNArvinas   1.22   
34.0%
0%
EWTXEdgewise Therapeutics   1.88   
53.0%
0%
MLYSMineralys Therapeutics,   2.22   
63.0%
0%
INCYIncyte   3.22   
91.0%
0%
CRNXCrinetics Pharmaceuticals   3.52   
100.0%
0%

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios